OnPART diagnostic data

Top-line data from 384 patients with breast, colorectal, lung or ovarian cancer who were receiving a standard chemotherapy regimen in an initial study showed that OnPART met the primary endpoint with a sensitivity and specificity AUC of >0.9 for correctly identifying patients at risk for 6 common side effects of chemotherapy. To meet the endpoint, OnPART need an AUC of >0.8. Reported adverse events included nausea and vomiting, mouth sores, diarrhea, fatigue, cognitive dysfunction and peripheral neuropathy. Chemotherapy regimens included dose-dense doxorubicin, cyclophosphamide and paclitaxel for breast cancer, oxaliplatin-based regimens for colorectal cancer and carboplatin plus paclitaxel-based regimens for lung and ovarian cancer. ...